Edition:
United Kingdom

Healthcare

UPDATE 2-Amarin raises revenue forecasts after getting OK to promote Vascepa heart benefits

Dec 13 U.S. health regulators on Friday approved expanding the heart benefit claims Amarin Corp can make in promoting its drug Vascepa to include reducing the risk of heart attacks and strokes in high-risk patients, opening a multibillion-dollar market opportunity.

13 Dec 2019

UPDATE 1-Bristol-Myers wins $752 million in U.S. patent case against Gilead

Dec 13 Bristol-Myers Squibb Co on Friday said it won a $752 million jury verdict against Gilead Sciences Inc in a U.S. patent dispute relating to technology for treating cancer.

13 Dec 2019

UPDATE 2-FDA panel votes unanimously in favor of Horizon's thyroid eye disease drug

Dec 13 Independent advisers to the U.S. Food and Drug Administration on Friday voted unanimously in favor of Horizon Therapeutics Plc's experimental treatment for active thyroid eye disease, taking the drug closer towards potential approval.

13 Dec 2019

FDA says Amarin can market fish-oil derived therapy for reducing heart attack risk

Dec 13 U.S. health regulators on Friday approved expanding the heart benefit claims Amarin Corp can make in promoting its drug Vascepa to include reducing the risk of heart attacks and strokes in high-risk patients, opening a multibillion-dollar market opportunity.

13 Dec 2019

FDA panel votes in favour of Horizon's active thyroid eye disease drug

Dec 13 Independent advisers to the U.S. Food and Drug Administration on Friday unanimously voted in favor of Horizon Therapeutics Plc's experimental treatment for thyroid eye disease (TED), taking the drug a step towards potential approval.

13 Dec 2019
Healthcare
GlaxoSmithKline PLC 1,725.00 -1.10%
AstraZeneca PLC 7,217.00 -0.80%
Smith & Nephew PLC 1,734.50 +2.21%

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.